Monza, Italy

Alessandro Baglioni


Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 51(Granted Patents)


Location History:

  • Monza, IT (1981)
  • Milan, IT (1983)

Company Filing History:


Years Active: 1981-1983

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Alessandro Baglioni in Pharmaceutical Compositions

Introduction

Alessandro Baglioni is a notable inventor based in Monza, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of acute pulmonary edema and various types of shock. With a total of 3 patents to his name, Baglioni's work is recognized for its innovative approach to medical treatments.

Latest Patents

Baglioni's latest patents focus on the treatment of acute pulmonary edema using arginine esters. These pharmaceutical compositions are designed to relieve acute pulmonary edema and different types of shock, including anaphylactic shock and shock induced by bacterial endotoxins. The compositions consist of solutions of an ester of L-arginine with an aliphatic alcohol in water, maintaining a pH between 5.5 and 8.5. They can be provided in unit dosage forms containing 0.25-100 mg of active substance per kilogram of body weight and are administered through the parenteral route. Notably, these compositions have been found to be more effective than traditional treatments such as aspirin and aprotinin.

Career Highlights

Alessandro Baglioni is currently associated with Italfarmaco Spa, where he continues to develop innovative pharmaceutical solutions. His work has garnered attention for its potential to improve patient outcomes in critical medical situations.

Collaborations

Baglioni collaborates with Giancarlo Sportoletti, contributing to the advancement of pharmaceutical research and development.

Conclusion

Alessandro Baglioni's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to improving medical treatments. His work continues to pave the way for advancements in the management of acute pulmonary conditions and shock.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…